The following data is part of a premarket notification filed by Sebia with the FDA for Hydrashift 2/4 Daratumumab.
| Device ID | K190851 |
| 510k Number | K190851 |
| Device Name: | HYDRASHIFT 2/4 Daratumumab |
| Classification | Immunoelectrophoretic, Immunoglobulins, (g, A, M) |
| Applicant | Sebia 1705 Corporate Drive, Suite 400 Norcross, GA 30093 |
| Contact | Karen Anderson |
| Correspondent | Karen Anderson Sebia 1705 Corporate Drive, Suite 400 Norcross, GA 30093 |
| Product Code | CFF |
| CFR Regulation Number | 866.5510 [🔎] |
| Decision | Substantially Equivalent (SESE) |
| Type | Special |
| 3rd Party Reviewed | No |
| Combination Product | No |
| Date Received | 2019-04-02 |
| Decision Date | 2019-05-02 |
| Device Identifier | submissionNumber | Supplement |
|---|---|---|
| 03607360046395 | K190851 | 000 |